We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Role of FDG PET in Radiation Treatment Planning for Head and Neck Cancers

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00230269
First Posted: September 30, 2005
Last Update Posted: July 12, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Information provided by:
Stanford University
  Purpose
In patients with cancer of the head and neck and rectum, knowing the exact location of the tumor is important for designing the radiation field to ensure delivery of high dose of radiation to the tumor while sparing surrounding normal tissues. A new medical imaging method which is a combination of positron emission tomography (PET) and computed tomography (CT) scan, has shown promise in helping the radiation oncologist in defining the exact location and extent of the tumor in certain cancers such as lung cancers. Therefore the purpose of this study is to determine if these imaging methods can be used in combination with the standard radiation treatment planning procedure to improve the accuracy to targeting your tumor with radiation. In addition the PET-CT scan, similar to the PET scan alone with better resolution, can be used to determine whether the tumor has spread to any part of the body outside of the head and neck sites.

Condition Intervention
Head and Neck Cancer Procedure: PET-CT

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Role of FDG PET in Radiation Treatment Planning for Head and Neck Cancers

Resource links provided by NLM:


Further study details as provided by Stanford University:

Enrollment: 5
Study Start Date: May 2003
Study Completion Date: November 2007
Primary Completion Date: June 2006 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients who are scheduled to receive radiation therapy for head and neck cancer at Stanford.
Criteria

Inclusion Criteria:Patients who are scheduled to receive radiation therapy for head and neck cancer at Stanford.

Exclusion Criteria:Non-Stanford patients.

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00230269


Locations
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Investigators
Principal Investigator: Quynh-Thu Le Stanford University
  More Information

ClinicalTrials.gov Identifier: NCT00230269     History of Changes
Other Study ID Numbers: ENT0005
First Submitted: September 28, 2005
First Posted: September 30, 2005
Last Update Posted: July 12, 2012
Last Verified: July 2012

Additional relevant MeSH terms:
Head and Neck Neoplasms
Neoplasms by Site
Neoplasms